Evidence map›Paper›PMID 41480309›Full record

ArticleBlood neoplasia2026

Bone marrow immune cell composition reflects multiple myeloma progression and affects treatment response.

Anna Maria Corsale, Mojtaba Shekarkar Azgomi, Emilia Gigliotta, Marta Di Simone, Paola Pacelli, Francesca Cioffi, Elena Bestoso, Donatella Raspadori, Alessandro Gozzetti, Antonio Solimando and 17 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood neoplasia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Anna Maria CorsaleCentral Laboratory of Advanced Diagnosis and Biomedical Research, University of Palermo, Palermo, Italy.
Mojtaba Shekarkar AzgomiCentral Laboratory of Advanced Diagnosis and Biomedical Research, University of Palermo, Palermo, Italy.
Emilia GigliottaDepartment of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy.
Marta Di SimoneCentral Laboratory of Advanced Diagnosis and Biomedical Research, University of Palermo, Palermo, Italy.
Paola PacelliDepartment of Medicine, Surgery and Neurosciences, University of Siena, Policlinico S. Maria alle Scotte, Siena, Italy.
Francesca CioffiDepartment of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy.
Elena BestosoHematology Unit, University of Siena, Azienda Ospedaliera Universitaria Senese, Siena, Italy.
Donatella RaspadoriHematology Unit, University of Siena, Azienda Ospedaliera Universitaria Senese, Siena, Italy.
Alessandro GozzettiDepartment of Medicine, Surgery and Neurosciences, University of Siena, Policlinico S. Maria alle Scotte, Siena, Italy.
Antonio SolimandoUnit of Internal Medicine "Guido Baccelli," Department of Precision and Regenerative Medicine and Ionian Area, University of Bari "Aldo Moro" Medical School, Bari, Italy.
Paula TabaresDepartment of Medicine II, University Hospital of Würzburg, Würzburg, Germany.
Andreas BeilhackDepartment of Medicine II, University Hospital of Würzburg, Würzburg, Germany.
Maria SpecialeDepartment of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy.
Giusy CorsaleDepartment of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy.
Miriam SciortinoCentral Laboratory of Advanced Diagnosis and Biomedical Research, University of Palermo, Palermo, Italy.
Cristina AquilinaDepartment of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy.
Fulvio BrucatoCentral Laboratory of Advanced Diagnosis and Biomedical Research, University of Palermo, Palermo, Italy.
Michele CeaHematology Unit, Department of Internal Medicine, University of Genoa, IRCSS Ospedale Policlinico San Martino, Genova, Italy.
Renato ZambelloHematology Unit, Department of Medicine, University of Padova, Padua, Italy.
Francesca GarofanoDepartment of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy.
Marta BiondoHematology Section, Department of General Surgery and Medical-Surgical Specialties, University of Catania, Catania, Italy.
Francesca BuffaCentral Laboratory of Advanced Diagnosis and Biomedical Research, University of Palermo, Palermo, Italy.
Nadia CaccamoCentral Laboratory of Advanced Diagnosis and Biomedical Research, University of Palermo, Palermo, Italy.
Francesco DieliCentral Laboratory of Advanced Diagnosis and Biomedical Research, University of Palermo, Palermo, Italy.
Serena MeravigliaCentral Laboratory of Advanced Diagnosis and Biomedical Research, University of Palermo, Palermo, Italy.
Sergio SiragusaDepartment of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy.
Cirino BottaDepartment of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The progression of multiple myeloma (MM) is characterized by intricate interactions between clonal plasma cells and the bone marrow (BM) microenvironment. In this study, we conducted a comprehensive analysis of BM immune cell composition spanning from premalignant stages to MM, using FlowCT, a semiautomated workspace empowered to analyze large data sets. Our cohort comprised 159 patients, covering monoclonal gammopathy of undetermined significance, smoldering MM, and MM, with most undergoing treatment with a daratumumab-based regimen. The evolving disease showed alterations in immune cell populations, including a reduction in the granulocyte-to-lymphocyte ratio (GLR) and granulocyte-to-T-lymphocyte (GTL) ratio, alongside an increase in T lymphocytes. Higher baseline levels of BM GLR and GTL ratio were associated with extended progression-free survival. Moreover, improved outcomes were observed in patients with a higher GTL ratio treated with daratumumab-based regimens. Furthermore, autologous BM-derived granulocytes enhance daratumumab-mediated cytotoxicity against primary autologous neoplastic plasma cells, unveiling a novel BM-granulocyte-dependent mechanism of action for daratumumab in patients with MM. These findings emphasize the dynamic nature of the BM immune compartment during MM progression and underscore the prognostic significance of immune cell composition in guiding therapeutic approaches and enhancing patient outcomes.

Identifiers

PMID41480309
PMCPMC12754204

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.